These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33662418)

  • 1. SARS-CoV-2: Insights into its structural intricacies and functional aspects for drug and vaccine development.
    Kaur M; Sharma A; Kumar S; Singh G; Barnwal RP
    Int J Biol Macromol; 2021 May; 179():45-60. PubMed ID: 33662418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics.
    Yesudhas D; Srivastava A; Gromiha MM
    Infection; 2021 Apr; 49(2):199-213. PubMed ID: 32886331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
    Mondal T; Shivange G; Habieb A; Tushir-Singh J
    Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
    Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of Nonstructural Protein 1 from SARS-CoV-2.
    Clark LK; Green TJ; Petit CM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33234675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural biology of SARS-CoV-2 and implications for therapeutic development.
    Yang H; Rao Z
    Nat Rev Microbiol; 2021 Nov; 19(11):685-700. PubMed ID: 34535791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive selection as a key player for SARS-CoV-2 pathogenicity: Insights into ORF1ab, S and E genes.
    Emam M; Oweda M; Antunes A; El-Hadidi M
    Virus Res; 2021 Sep; 302():198472. PubMed ID: 34118359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structural basis of accelerated host cell entry by SARS-CoV-2†.
    Seyran M; Takayama K; Uversky VN; Lundstrom K; Palù G; Sherchan SP; Attrish D; Rezaei N; Aljabali AAA; Ghosh S; Pizzol D; Chauhan G; Adadi P; Mohamed Abd El-Aziz T; Soares AG; Kandimalla R; Tambuwala M; Hassan SS; Azad GK; Pal Choudhury P; Baetas-da-Cruz W; Serrano-Aroca Á; Brufsky AM; Uhal BD
    FEBS J; 2021 Sep; 288(17):5010-5020. PubMed ID: 33264497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into SARS-CoV-2 proteins.
    Arya R; Kumari S; Pandey B; Mistry H; Bihani SC; Das A; Prashar V; Gupta GD; Panicker L; Kumar M
    J Mol Biol; 2021 Jan; 433(2):166725. PubMed ID: 33245961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.
    Huang SW; Wang SF
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review.
    Bhat EA; Khan J; Sajjad N; Ali A; Aldakeel FM; Mateen A; Alqahtani MS; Syed R
    Int Immunopharmacol; 2021 Jun; 95():107493. PubMed ID: 33721758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy.
    Toelzer C; Gupta K; Berger I; Schaffitzel C
    Acta Crystallogr D Struct Biol; 2023 Feb; 79(Pt 2):111-121. PubMed ID: 36762857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses.
    Kirtipal N; Bharadwaj S; Kang SG
    Infect Genet Evol; 2020 Nov; 85():104502. PubMed ID: 32798769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS coronavirus 2: from genome to infectome.
    Rastogi M; Pandey N; Shukla A; Singh SK
    Respir Res; 2020 Dec; 21(1):318. PubMed ID: 33261606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.
    Kalathiya U; Padariya M; Fahraeus R; Chakraborti S; Hupp TR
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
    Mohammed MEA
    Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.